ArticleInternal medicine (Tokyo, Japan)2018
Relapsed Myasthenia Gravis after Nivolumab Treatment.
Article in Internal medicine (Tokyo, Japan), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 34 citations in OpenAlex.
- Long-Term Response Without Immune-Related Adverse Events to Atezolizumab Treatment in TMB-High Thymoma: A Case Report from the KOSMOS-II Study.Journal of clinical medicine · 2026Article
- Peripheral nervous system immune-related adverse events due to checkpoint inhibition.Nature reviews. Neurology · 2024Review
- Immune Checkpoint Inhibitors in Patients with Pre-existing Neurologic Autoimmune Disorders.Current neurology and neuroscience reports · 2023Review
- Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Review
- Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies.Cancer immunology, immunotherapy : CII · 2022Review
- How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update.Journal of neurology · 2022Article
- Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature.Frontiers in pharmacology · 2022Review
- Myasthenia gravis induced or exacerbated by immune checkpoint inhibitors: a rising concern.BMJ case reports · 2021Article
- Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update.Journal of clinical medicine · 2021Review
- Immune Checkpoint Inhibitors and Neurotoxicity.Current neuropharmacology · 2021Review
- Immune Checkpoint Inhibitor-Induced Myasthenia Gravis.Frontiers in neurology · 2020Review
- Pathomechanisms and Clinical Implications of Myasthenic Syndromes Exacerbated and Induced by Medical Treatments.Frontiers in molecular neuroscience · 2020Review
- Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review.Eye and brain · 2020Review
- Myasthenia gravis and myopathy after nivolumab treatment for non-small cell lung carcinoma: A case report.Thoracic cancer · 2019Article
- Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations.Frontiers in pharmacology · 2019Review
- Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia.Annals of clinical and translational neurology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nivolumab is a newly introduced promising therapy for treating lung cancer that restores the anti-tumor immunity by disrupting programmed cell death-1-mediated immuno-suppressive signaling. Although "new-onset" autoimmune diseases are well-known immune-related adverse events, whether or not nivolumab exacerbates "pre-existing" autoimmune disease remains unclear. We herein report a patient with "pre-existing" myasthenia gravis in whom nivolumab was administered that flared up after the treatment with nivolumab. Regardless of the disease stability, nivolumab has the potential to exacerbate an autoimmune disease, and we must pay close attention to each patient's medical history before administering this agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.